10x Genomics Cuts FY24 Revenue Guidance From $640M-$5660M To $595M-$605M Vs. $636.595M Est
Portfolio Pulse from Benzinga Newsdesk
10x Genomics has revised its FY24 revenue guidance downwards from $640M-$660M to $595M-$605M, which is below the estimated $636.595M.
October 29, 2024 | 8:11 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
10x Genomics has reduced its FY24 revenue guidance to $595M-$605M, which is below the market estimate of $636.595M. This revision may negatively impact investor sentiment and the stock price in the short term.
The downward revision of revenue guidance suggests potential challenges in achieving previous targets, which could lead to negative investor sentiment and a decrease in stock price. The guidance is significantly below market expectations, increasing the likelihood of a negative impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100